When Phospholipase A2 Receptor Meets Hepatitis B: Navigating Primary vs. Secondary Membranous Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0697; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Rituximab was planned for high-risk MN; however, pre-treatment screening revealed active HBV infection with positive HBsAg, HBeAg and HBV DNA >20,000 IU/mL...The patient was transitioned to entecavir for viral suppression and subsequently cleared for immunosuppression...This case highlights the importance of individualized management and careful sequencing of antiviral and immunosuppressive therapy to reduce HBV reactivation risk while treating progressive nephrotic syndrome. Figure 1: Renal biopsy with immunofluorescense showing PLA2R positivity"
Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Glomerulonephritis • Heart Failure • Hepatitis B • Hepatology • Hypertension • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Renal Disease
|
|
Noorelle Khan; Lonnie Thach; Samih H. Nasr
|